StemCell Therapy

AI is rocking medical diagnosis with its potential to incite drastic improvements to hospital processes. AI can process images and patient health records with more accuracy and expediency than humans are capable of, lessening physician workload, reducing misdiagnosis, and empowering clinical staff to provide more value.

While early moving hospitals are already extracting value from AI in medical diagnosis, most US hospitals are at the very early stage of the AI transformation curve - and they risk falling behind if they don't move now.

In this report, Business Insider Intelligence examines the value of AI applications in three high-value areas of medical diagnosis - imaging, clinical decision support, and personalized medicine - to illustrate how the tech can drastically improve patient outcomes, lower costs, and increase productivity.

We look at US health systems that have effectively applied AI in these use cases to illustrate where and how providers should implement AI. Finally, we examine how a leading US health system validates AI partners and internally organizes its AI strategy to offer provider organizations a template for AI innovation.

The companies mentioned in this report are: Aidoc, Allscripts, Amazon, Arterys, Boston Gene, Cabell Huntington Hospital, Cerner, Cleveland Clinic, Epic, Geisinger Health System, Google, HCA Healthcare, IBM, iCAD, IDx, Intermountain Healthcare, Johns Hopkins, Meditech, Microsoft, Mount Sinai, NorthShore University HealthSystem, Oak Street Health, Stanford University, Tempus, UCI Health System, Unanimous AI, Verily, Viz.ai, and Yale New Haven Hospital.

Here are some of the key takeaways from the report:

In full, the report:

Want to learn more about the fast-moving world of digital health? Here's how to get access:

Read more:
AI IN MEDICAL DIAGNOSIS: How top US health systems are reacting to the disruptive force of AI by revolutionizi - Business Insider India

This entry was posted on February 14, 2020 at 4:47 am and is filed under Personalized Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |